# Alzheimer's Disease and IntranasalFluticasone Propionate in the FDAMedWatch Adverse Events Database

<sup>4</sup> Steven Lehrer<sup>a,\*</sup> and Peter H. Rheinstein<sup>b</sup>

<sup>5</sup> <sup>a</sup>Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA

<sup>6</sup> <sup>b</sup>Severn Health Solutions, Severna Park, MD, USA

Accepted 9 January 2018

### 7 Abstract.

- Background: Studies of Alzheimer's disease suggest that neuroinflammation or deranged brain wound healing may be a
- <sup>9</sup> cause of some cases. But a placebo controlled study showed no effect at all on Alzheimer's disease of low dose oral prednisone
- after one year. Introducing the steroid directly into the hippocampus and rhinencephalon via the nose, as happens in hay fever subjects, could be more effective.
- **Objective:** In the present study, we analyzed FDA MedWatch data for intranasal fluticasone propionate (Flonase) to determine the frequency of Alzheimer's disease as an adverse event reported after use of the medication.
- Methods: Machine-readable data from MedWatch, including adverse drug reaction reports from manufacturers, are part of
- a public database. We used the online tool *eHealthMe* to query the database.
- **B** a public database. We used the omine tool encounter to query the database.
- **Results:** By September 20, 2017, 35,221 people reported side effects to MedWatch after taking Flonase. Among them,
- 9 people (0.03%) had Dementia Alzheimer's type. By October 3, 2017, 185,636 people reported side effects after taking
  Lipitor. Among them, 243 people (0.13%) had Dementia Alzheimer's type. The lower incidence of Alzheimer's dementia in
  Lipitor. Among them, 243 people (0.13%) had Dementia Alzheimer's type. The lower incidence of Alzheimer's dementia in
- the Flonase group compared to the Lipitor group was significant (p < 0.001, Fisher exact test, two tailed).
- 20 **Conclusion:** Long term use of oral non-steroidal anti-inflammatory drugs (NSAIDs) is linked with reduced risk of developing
- Alzheimer's disease. Data from MedWatch suggest that fluticasone propionate administered intranasally might have a similar
   preventive effect to ibuprofen. Perhaps combining ibuprofen and Flonase could be therapeutic. Further studies would be
   desirable.

24 Keywords: Alzheimer's disease, brain, dementia, intranasal, steroids

Studies of Alzheimer's disease suggest that neuroinflammation [1] or deranged brain wound healing [2] may be responsible for some cases. Injury to the brain from trauma or irradiation may initiate the process [3]. The characteristic pathologic plaques and tangles are a non-specific result of the disease process, not a cause [4].

Biochemical and neuropathological studies of brains from individuals with Alzheimer's disease provide clear evidence for an activation of inflammatory pathways and glial inflammation [5]. If part of the neuroinflammation is autoimmune, the predominance of Alzheimer's disease in women could be explained, since autoimmune diseases are much more common in women than men.

However, there is no beneficial effect of nonsteroidal anti-inflammatory drugs (NSAIDs), such as naproxen, rofecoxib, or ibuprofen, on cognition or overall Alzheimer's disease severity. Oral NSAIDs have no value as an Alzheimer's disease treatment [6].

Chou et al. showed a reduction in risk of Alzheimer's disease in rheumatoid arthritis patients

43

44

45

46

34

1

ISSN 2542-4823/17/\$35.00 © 2017 – IOS Press and the authors. All rights reserved

<sup>\*</sup>Correspondence to: Steven Lehrer, MD, Box 1236 Radiation Oncology, Mount Sinai Medical Center, 1 Gustave L. Levy Place, New York, NY 10029, USA. E-mail: stevenlehrer@hotmail.com.

on prednisone [7]; unadjusted the effect is almost 47 significant (p=0.1). The reduction is quite remark-48 able, given the tiny amounts of prednisone that reach 49 the brain after an oral dose due to tight plasma pro-50 tein binding. Balis et al. found that the cerebrospinal 51 fluid/plasma ratio of dexamethasone is 0.15, of pred-52 nisolone 0.079 [8]. Such minute amounts of steroid in 53 the brain presumably have a tiny or negligible effect. 54 Indeed, another placebo controlled study showed no 55 effect at all on Alzheimer's disease of low dose oral 56 prednisone after one year [9]. 57

Introducing the steroid directly into the hippocampus and rhinencephalon via the nose, as happens in hay fever subjects, could be more effective. In the present study, we analyzed FDA MedWatch data for intranasal fluticasone propionate (Flonase) to determine the frequency of Alzheimer's disease as an adverse event reported after use of the medication.

# 65 METHODS

We used data from MedWatch, the Food and 66 Drug Administration (FDA) Safety Information and 67 Adverse Event Reporting Program [10]. MedWatch 68 was organized in 1993 to collect data regarding 69 adverse events in healthcare. An adverse event is 70 any undesirable experience associated with the use 71 of a medical product. The MedWatch system collects 72 reports of adverse reactions and quality problems, 73 primarily due to drugs and medical devices, but 74 also for other FDA-regulated products (e.g., dietary 75 supplements, cosmetics, medical foods, and infant 76 formulas). 77

MedWatch offers a choice between a voluntary 78 reporting form, designed primarily for health care 79 professionals and the general public, and a manda-80 tory adverse event reporting service (AERS) form, 81 available to manufacturers, importers, and medical 82 product user facilities that manage and store medical 83 products. The latter group is required by law to sub-84 mit the mandatory form immediately upon discovery 85 of a product malfunction. Printable mail-in forms are 86 available as an alternative to the online submission 87 system [11]. 88

A MedWatch report of an adverse event does not establish causation. For any given report, there is no certainty that the drug in question caused the reaction. The adverse event may have been related to the underlying disease being treated, perhaps caused by another drug being taken concurrently, or something else. Machine-readable data from MedWatch, including adverse drug reaction reports from manufacturers, are part of a public database. We used the online tool *eHealthMe* to query the database [12, 13]. Data are exclusively from MedWatch, not from social media [14].

### RESULTS

By September 20, 2017, 35,221 people reported side effects to FDA after taking Flonase (intranasal fluticasone propionate). Among them, 9 people (0.03%) had Dementia Alzheimer's type (Fig. 1).

By October 3, 2017, 185,636 people reported side effects after taking Lipitor (atorvastatin). Among them, 243 people (0.13%) had Dementia Alzheimer's type (Fig. 1). In a large-scale randomized controlled trial evaluating statin therapy as a treatment for mild to moderate Alzheimer disease, atorvastatin was not associated with significant clinical benefit over 72 weeks [15].

By October 8, 2017, 102,006 people reported side effects when taking Ibuprofen. Among them, 34 people (0.03%) had Dementia Alzheimer's type, a proportion identical to Flonase (Fig. 1). Ibuprofen reduces the risk of Alzheimer's disease, although, as was mentioned, it is not a treatment [16].

The lower incidence of Alzheimer's dementia in the Flonase group compared to the Lipitor group was significant (p < 0.001, Fisher exact test, two tailed).

80% of the people taking Flonase were over 60; 93% of the people taking Lipitor were over 60; 89% of the people taking ibuprofen were over 60 (Table 1). 89% of the patients using Flonase were female, versus 56% of the patients taking Lipitor and 82% of the patients taking ibuprofen. The most common other conditions in patients who reported Alzheimer's disease are listed in Table 2. Drugs most often used by patients who reported Alzheimer's disease are listed in Table 3. Additional side effects in patients who reported Alzheimer's disease are listed in Table 4.

# DISCUSSION

One case control study demonstrated that hay fever and other allergies were associated with diminished risk of Alzheimer's disease (odds ratio 0.6) [17]. Hay fever patients' use of nasal glucocorticoids might be lessening their risk of Alzheimer's disease and functioning as a treatment in early cases. Another analysis found no effect of hay fever [18], but subjects' use

97 98 99

96

100 101

102

103 104 105

106

107

108

109

110 111

112 113

114

116 117 118

> 119 120 121

> 122 123

124 125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142




Fig. 1. MedWatch Alzheimer's disease reports in patients using Flonase, Lipitor (atorvastatin), and ibuprofen by year. Number of reports is above the corresponding bar.

of anti-allergy anticholinergics, such as diphenhydramine, may have confused the results by raising
risk of Alzheimer's disease [19].

Both pregnenolone and progesterone arrive in the brain after nasal administration [20]. Intranasal regular insulin improves cognition in Alzheimer's disease, probably because of its brain effects [21]; and the kinetics of intranasal ACTH suggest that it gets into the brain [22]. Therefore, intranasal fluticasone probably gets into the brain via the nose, as well.

The rodent hippocampus is particularly sensi-153 tive to glucocorticoids. While glucocorticoids are 154 essential for an effective stress response, their 155 oversecretion was originally hypothesized to con-156 tribute to age-related hippocampal degeneration. 157 However, conflicting findings were reported on 158 whether prolonged exposure to elevated glucocor-159 ticoids endangered the hippocampus; and whether 160 the primate hippocampus, where Alzheimer's disease 161 originates, even responds to glucocorticoids as the 162 rodent hippocampus does [23]. 163

Our use of adverse event drug reports has distinct 164 problems. One problem is that the analysis does not 165 include all those taking Flonase, ibuprofen or Lipi-166 tor who did not have any adverse reaction (including 167 Alzheimer's disease) to any drug they were taking. 168 This problem might be addressed by prescription 169 records (or company sales records) indicating how 170 many took the drug. A big data approach could 171 involve a large national database sample from Tai-172 wan or South Korea, tracking medication usage and 173 later medical diagnoses. 174

Table 1 Age distribution of patients using Flonase, Lipitor, or ibuprofen

Age	Flonase	Lipitor	Ibuprofen
10-19	0	0.63%	3.70%
20-29	0	0.00%	0.00%
30–39	0	0.63%	3.70%
40–49	0	0.00%	0.00%
50-59	20%	5.70%	3.70%
60+	80%	93.04%	88.89%

Another problem in our analysis is that those who reported adverse effects were likely also taking other medications, which may be associated with Alzheimer's disease, either increasing or decreasing the risk (some because they treat a disease that is a risk factor for Alzheimer's disease). This problem might be addressed more systematically by a big data analysis of MedWatch to seek drugs negatively associated with Alzheimer's disease. However, it is implausible that the patterns of other medications in our analysis were the same for those taking Flonase, ibuprofen, and Lipitor.

In a previous study, Lerner et al. found that delirium is an initial symptom in about 3% of patients diagnosed with Alzheimer's disease [24]. Medications are one of the biggest causes of delirium, especially benzodiazepines [25], which were common in patients taking atorvastatin as a concurrent medication. Dementia has been listed as a side effect of atorvastatin (and other statins), but might represent the confluence of two common disorders: hypercholesterolemia and dementia (which is not the same as Alzheimer's disease).

193

194

195

196

197

175

Flonase	Lipitor	Ibuprofen	
Trigeminal Neuralgia (1 person, 11.11%)	Sleep Disorder (13 people, 5.35%)	Rheumatoid Arthritis (7 people, 20.59%)	
Sinus Disorder (1 person, 11.11%)	Depression (9 people, 3.70%)	Preventive Health Care (6 people, 17.65%)	
Metastases To Spine (1 person, 11.11%)	Diabetes (8 people, 3.29%)	Osteoporosis (4 people, 11.76%)	
High Blood Pressure (1 person, 11.11%)	Osteoporosis (7 people, 2.88%)	Multiple Myeloma (4 people, 11.76%)	
Depression (1 person, 11.11%)	Ill-Defined Disorder (7 people, 2.88%)	Chronic Obstructive Pulmonary Disease	
		(4 people, 11.76%)	
Other drugs mo	Table 3 st commonly used by patients who reported Al	zheimer's disease	

 Table 2

 Most common other conditions in patients who reported Alzheimer's disease

Other drugs most commonly used by patients who reported Alzheimer's disease				
Lipitor	Ibuprofen			
Aricept (47 people, 19.34%)	Aspirin (14 people, 41.18%)			
Aspirin (21 people, 8.64%)	Lorazepam (10 people, 29.41%)			
Namenda (20 people, 8.23%)	Humira (9 people, 26.47%)			
Plavix (14 people, 5.76%)	Norvasc (8 people, 23.53%)			
Nexium (13 people, 5.35%)	Cymbalta (7 people, 20.59%)			
	Lipitor Aricept (47 people, 19.34%) Aspirin (21 people, 8.64%) Namenda (20 people, 8.23%) Plavix (14 people, 5.76%)			

 Table 4

 Other common side effects in patients who reported Alzheimer's disease

Flonase	Lipitor	Ibuprofen
Pneumonia (5 people, 55.56%)	Memory Loss (55 people, 22.63%)	Fall (9 people, 26.47%)
Pain (5 people, 55.56%)	Stroke (24 people, 9.88%)	Breathing Difficulty (8 people, 23.53%)
Headache (5 people, 55.56%)	Depression (21 people, 8.64%)	Memory Loss (7 people, 20.59%)
Gastroesophageal Reflux Disease (5 people, 55.56%)	Diarrhea (20 people, 8.23%)	Drug Ineffective (7 people, 20.59%)
Fall (5 people, 55.56%)	Pneumonia (18 people, 7.41%)	Injury (6 people, 17.65%)

204

It is possible that individuals already suffering some degree of dementia would be less bothered by seasonal rhinitis or have less access to over the counter drugs such as fluticasone nasal spray. These phenomena could account for part of the observed lower incidence of Dementia Alzheimer's type reports in patients using Flonase<sup>®</sup>.

Nevertheless, long term use of oral non-steroidal 205 anti-inflammatory drugs is linked with reduced risk 206 of developing Alzheimer's disease [26]. These drugs 207 also potentially inhibit brain wound healing [2]. We 208 posit that NSAIDS and steroids both inhibit wound 209 healing in the brain (a well-known fact in the periph-210 ery). We further suggest that the lower incidence of 211 AD due to NSAIDS and steroids may be through 212 inhibiting brain wound healing. That is, there is an 213 initial event, and the brain response is what causes 214 the dementia which we call "Alzheimer's disease." 215 NSAIDS and steroids may be preventive through a 216 wound healing inhibition mechanism. Our hypothe-217 sis is consistent with the idea that amyloid and tau and 218 their cascade of pathology are both a brain response 219 linked to the genesis of the problem [4]. 220

In summary, data from MedWatch presented here suggest that fluticasone propionate administered intranasally might have a similar preventive effect to ibuprofen. Glucocorticoids, moreover, inhibit wound healing. Perhaps combining ibuprofen and Flonase could be therapeutic. Further studies would be desirable.

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

# **CONFLICT OF INTEREST**

The authors have no conflict of interest to report.

## REFERENCES

- McManus RM, Heneka MT (2017) Role of neuroinflammation in neurodegeneration: New insights. *Alzheimers Res Ther* 9, 14.
- [2] Lehrer S, Rheinstein PH (2016) A derangement of the brain wound healing process may cause some cases of Alzheimer's disease. *Discov Med* 22, 43-46.
- [3] Lehrer S, Rheinstein PH, Rosenzweig KE (2017) Association of radon background and total background ionizing radiation with Alzheimer's disease deaths in U.S. states. *J Alzheimers Dis* 59, 737-741.
- [4] Castellani RJ, Perry G (2014) The complexities of the pathology-pathogenesis relationship in Alzheimer disease. *Biochem Pharmacol* 88, 671-676.
- [5] D'Andrea MR, Cole GM, Ard MD (2004) The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. *Neurobiol Aging* 25, 675-683.
- [6] Miguel-Alvarez M, Santos-Lozano A, Sanchis-Gomar F, Fiuza-Luces C, Pareja-Galeano H, Garatachea N, Lucia A

(2015) Non-steroidal anti-inflammatory drugs as a treatment for Alzheimer's disease: A systematic review and meta-analysis of treatment effect. Drugs Aging 32, 139-147.

Chou RC, Kane M, Ghimire S, Gautam S, Gui J (2016) 252 [7] 253 Treatment for rheumatoid arthritis and risk of Alzheimer's disease: A nested case-control analysis. CNS Drugs 30, 254 1111-1120 255

240

250

251

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

281

287

288

289

290

291

292

- Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack [8] DG (1987) Differences in cerebrospinal fluid penetration of corticosteroids: Possible relationship to the prevention of meningeal leukemia. J Clin Oncol 5, 202-207.
- Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, [9] Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ (2000) A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 54, 588-593.
- [10] Kessler DA (1993) Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA 269, 2765-2768.
- Craigle V (2007) MedWatch: The FDA safety information [11] and adverse event reporting program. J Med Libr Assoc 95, 224
- US Department of Health and Human Services eHealthMe [12] study from FDA and social media reports [electronic source]. http://www.ehealthme.com/print/ds15829624
- Salihoglu M, Turhan V, Onem Y, Ulcay A, Uzun G, [13] Ay H (2013) Sudden hearing loss in a patient receiving piperacillin/tazobactam and daptomycin for diabetic foot infection. Scand J Infect Dis 45, 239-240.
- [14] Coloma PM, Becker B, Sturkenboom MC, van Mulligen 278 EM, Kors JA (2015) Evaluating social media networks in 279 280 medicines safety surveillance: Two case studies. Drug Saf 38, 921-930.
- Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters 282 [15] DD. Jones RW. Schwam E. Schindler R. Hev-Hadavi J. 283 DeMicco DA, Breazna A (2010) Randomized controlled 284 trial of atorvastatin in mild to moderate Alzheimer disease: 285 LEADe. Neurology 74, 956-964. 286
  - [16] Vlad SC, Miller DR, Kowall NW, Felson DT (2008) Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70, 1672-1677.
  - [17] Shalat SL, Seltzer B, Pidcock C, Baker Jr EL (1987) Risk factors for Alzheimer's disease: A case-control study. Neurology 37, 1630-1633.

- Breteler MM, van Duijn CM, Chandra V, Fratiglioni L, [18] Graves AB, Hevman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA, et al. (1991) Medical history and the risk of Alzheimer's disease: A collaborative re-analysis of casecontrol studies. EURODEM Risk Factors Research Group. Int J Epidemiol 20(Suppl 2), S36-S42.
- Risacher SL, McDonald BC, Tallman EF, West JD, Far-[19] low MR. Unverzagt FW. Gao S. Boustani M. Crane PK. Petersen RC, Jack Jr CR, Jagust WJ, Aisen PS, Weiner MW, Saykin AJ, Alzheimer's Disease Neuroimaging Initiative (2016) Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol 73, 721-732.
- [20] Ducharme N, Banks WA, Morley JE, Robinson SM, Niehoff ML, Mattern C, Farr SA (2010) Brain distribution and behavioral effects of progesterone and pregnenolone after intranasal or intravenous administration. Eur J Pharmacol 641 128-134
- Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, [21] Trittschuh EH, Dahl D, Caulder E, Neth B, Montine TJ, Jung Y, Maldjian J, Whitlow C, Friedman S (2017) Effects of regular and long-acting insulin on cognition and Alzheimer's disease biomarkers: A pilot clinical trial. J Alzheimers Dis 57. 1325-1334.
- Lehrer S, Rheinstein P (2015) Two compartment model [22] of MSH/ACTH may be a surrogate for intranasal insulin central nervous system kinetics. https://www.j-alz.com/ content/two-compartment-model-mshacth-may-besurrogate-intranasal-insulin-central-nervous-system
- [23] Conrad CD (2008) Chronic stress-induced hippocampal vulnerability: The glucocorticoid vulnerability hypothesis. Rev Neurosci 19, 395-411.
- [24] Lerner AJ, Hedera P, Koss E, Stuckey J, Friedland RP (1997) Delirium in Alzheimer disease. Alzheimer Dis Assoc Disord 11. 16-20.
- Clegg A, Young JB (2011) Which medications to avoid in [25] people at risk of delirium: A systematic review. Age Ageing 40, 23-29.
- [26] Wyss-Coray T, Rogers J (2012) Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2, a006346.

333

5